AgomAb Therapeutics NV (AGMB) - Latest Market Data

Price & Market Data

Price: $11.05

Daily Change: -$0.45 / 4.07%

Daily Range: $11.00 - $12.30

Market Cap: $544,190,144

Daily Volume: 86,219

Performance Metrics

1 Week: 12.20%

1 Month: 8.70%

3 Months: -27.44%

6 Months: -20.96%

1 Year: -20.96%

YTD: -20.96%

About AgomAb Therapeutics NV (AGMB)

Stay ahead with market insights for AgomAb Therapeutics NV (AGMB). The stock is currently at 11.05, having moved by -$0.45 / 4.07% today. Its impressive market capitalization is 544,190,144. Find out how it has performed year-to-date and over 1, 3, 6, and 12 months.

Company Details

Employees: 62

Sector: Health technology

Industry: Biotechnology

Country: Belgium

Details

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.

Selected stocks

Lafayette Digital Acquisition Corp. I (ZKP)

Xsolla SPAC 1 (XSLL)

HCM III Acquisition Corp. (HCMA)

Invest Green Acquisition Corporation (IGAC)

Meshflow Acquisition Corp. (MESH)